← All trials
NCT05578456
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2022
- Primary completion
- Dec 31, 2025
- Completion date
- Dec 31, 2026
- First posted
- Oct 13, 2022
- Last posted
- Oct 13, 2022
- Enrollment
- 540
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Zhejiang UniversityLead sponsor
- Zhejiang UniversityOverall official - principal investigator
- Jiaxing Maternity and Child Health Care HospitalCollaborator
- Jinhua People's HospitalCollaborator
- Ningbo Women & Children's HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.